Coreg. Buy more. Save more.

CHICAGO & LONDON — This is a repeat of the version issued yesterday.
The Fitch Ratings global pharmaceutical team today published its ‘Quarterly Global Pharmaceutical R&D Pipeline’ report for the second quarter. The overview details the mos…

Branded drugs” domination of a market slips away with each generic launch. “Global sales of generic drugs will grow more than 20 percent annually to reach $80 billion by 2008, as healthcare providers turn increasingly to less-expensive, unpatented medicines,” said Graham Lewis, IMS vice president for pharma s…

Decision Resources (Waltham, MA), one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of key therapies, most notably GlaxoSmithKline’s Coreg and Roche’s Dilatrend/Kredex, will cause the chronic heart failure…

Flamel Technologies (Nasdaq: FLML) announced today that a payment
of $500,000 has been triggered in connection with the license
agreement it signed in 2007 with Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE). The agreement is for the development of a marketed
protein to be delivered using Flamel’s Medusa technology. …

Another one of the more common high blood pressure medicines are ones known as beta-blockers. Some of the most common brands include:
Levatal
Visken
Cartrol
Inderal
Sectral
Corgard
Blocadren
Coreg
Kerlone
There are numerous benefits with beta-blockers in treating high blood pressure symptoms. Among them are:
-The ability to slow down specific metabolic processes. …

Flamel Technologies (Nasdaq:FLML) today announced its financial
results for the second quarter of 2008 as well as the signing of two
further Medusa contracts with two current partners. Flamel currently
is working on Medusa projects with four of the top-ten and six of the
top-twenty pharmaceutical companies in the world.

Flamel reported total revenues of $9.2 million, compared to $7.4
million in the second quarter of 2007. P…

To: NATIONAL EDITORS

Contact: Jennifer Page of the Pharmaceutical Research and
Manufacturers of America, 1-202-835-3460

Honors Coreg Researchers at Capitol Hill Press Conference

WASHINGTON, Feb. 7 /PRNewswire-USNewswire/ — Pharmaceutica…

Q: I thoroughly enjoy your discussions on heart topics, and wondered if you could address one of sudden interest to me. It concerns ejection fraction. Echocardiograms indicate that mine has dropped from approximately 43 percent to an alarming 34 pe…

Dec. 6, 2001 — Heart failure is a major health concern in the U.S. Nearly 5 million people are living with this problem, and a half million are diagnosed every year. The most common cause is blockage of arteries in the heart, leading to damaged heart muscle and a weak pump. Other causes include heart infections — called endocarditis — and high blood pressure.

With all the development in heart …

GlaxoSmithKline P.L.C. said yesterday that it would buy a New Jersey firm with the U.S. rights to the triglyceride-fighter Lovaza for $1.65 billion in cash. Reliant Pharmaceuticals Inc., of Liberty Corner, has four artery- or heart-related medications on the market, including fast-growing Lova…